|
|
|
|
|
|
|
|
|
|
|
04.11.26 - 08:24
|
Astellas Pharma Inc. Profit Rises In H1 (AFX)
|
|
|
TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY) announced earnings for its first half that Increased, from the same period last yearThe company's earnings totaled JPY241.677 billion, or JPY134.47 p......
|
|
|
|
|
|
|
|
|
22.10.26 - 12:12
|
Astellas and AI Proteins sign miniprotein therapeutics deal (PBR)
|
|
|
Under the deal, AI Proteins is set to receive an upfront cash sum of more than $400m to design and optimise de novo miniproteins directed at targets selected
The post Astellas and AI Proteins sign miniprotein therapeutics deal appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
05.08.26 - 09:49
|
Astellas Pharma Inc. Reveals Climb In Q1 Profit (AFX)
|
|
|
TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY) reported earnings for its first quarter that Increased, from last yearThe company's earnings came in at JPY141.828 billion, or JPY78.96 per share. Th......
|
|
|
05.08.26 - 09:31
|
Astellas Pharma Earnings Up In Q1; Guides FY27 (AFX)
|
|
|
TOKYO (dpa-AFX) - Astellas Pharma Inc. (4503.T, ALPMF, ALPMY), a pharmaceutical and life sciences company, on Wednesday reported higher net income in the first quarter compared with the previous y......
|
|
|
|
|
|
|
21.06.26 - 19:06
|
Syntax Bio Announces Expanded Series A and Leadership Appointments (Business Wire)
|
|
|
Company raises additional capital to advance Cellgorithm™ platform, develop pancreatic beta cell therapy for type 1 diabetes and strengthen leadershipCHICAGO--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced an expanded Series A and new appointments to its executive leadership team, board of directors and scientific advisory board. The expansion brings Syntax Bio's Series A to $14.4 million and total funding to over $25 million.
The expanded round builds on support from Astellas Venture Management, Illumina Ventures, DCVC Bio, Civilization Ventures, EGB Capital, Mansueto Office, and Portal Innovations, and includes new participation from Draper Associates, Allegis Capital, LongGame, Mayo Clinic, the Illinois Department of Commerce and Economic Opportunity, Illinois Ventures, Exit Fund, Sigma Group, and Walder Ventures. Proceeds will support further advancement of the company's proprietary Cellgorithm™ platform and fund pancre...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
